An integrated ’omics approach highlights the role of epigenetic events to explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer
DNA methylation profiling (Illumina Infinium 450K) was performed on fresh frozen tumor biopsies taken before, during and after treatment from patients receiving neoadjuvant chemotherapy with or without the anti-angiogenic drug bevacizumab
Overall design
Bisulphite converted DNA from 290 samples from 132 patients were hybridised to the Illumina Infinium 150k Human Methylation Beadchip